YOLFTbeta
Solvonis Therapeutics plc

Solvonis Therapeutics plc

SVNS · LSE · Healthcare / Biotechnology

0.09GBX+0.00 (0.00%)

Price History

Full chart

Market Stats

Previous Close0.09
Open0.085
Day Range0.081 – 0.10
52-Week Range0.095 – 0.39
Volume31.15M
Market Cap8.10M
P/E (TTM)0.00
Forward P/E0.00
EPS0.00
Dividend Yield0.00%
Beta1.19
50-Day Avg0.1267
200-Day Avg0.2103

About

Solvonis Therapeutics plc, a clinical-stage biopharmaceutical company, develops medicines for addiction, psychiatry, and neurology disorders. The company develops SVN-001, an NMDA receptor antagonist that is in Phase III clinical trial for the treatment of severe alcohol use disorder; and SVN-002, which has completed Phase I clinical trial to treat moderate to severe alcohol use disorder. Its pre-clinical stage product consists of SVN-114 for the treatment of post-traumatic stress disorder; and SVN-015 for the treatment of stimulant use disorder. The company was formerly known as Graft Polymer (UK) Plc and changed its name to Solvonis Therapeutics plc in January 2025. Solvonis Therapeutics plc was incorporated in 2017 and is headquartered in London, the United Kingdom.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Anthony James Tennyson
  • Employees6
  • HeadquartersEccleston Yards, London, United Kingdom, SW1W 9NF, UK
  • Websitehttps://solvonis.com

Leadership

  • Mr. Anthony James TennysonCEO & Executive Director · b. 1976
  • Mr. Victor BolduevFounder · b. 1957
  • Mr. Ryan Paul NeatesChief Financial Officer · b. 1991
  • Dr. David John Nutt DM, FMedSci, FRCP, FRCPsych, FSB, Ph.D.Chief Scientific Advisor

Financials

Income Statement

Currency: GBP2018-05-312019-05-312020-05-312021-05-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue-29.00K330.00K690.86K219.00K542.00K587.00K00
Growth (%)--+1037.93%+109.35%-68.30%+147.49%+8.30%-100.00%-
Cost of Revenue8.00K13.00K46.00K173.14K164.00K593.00K721.00K0-
Gross Profit-8.00K16.00K284.00K517.72K55.00K-51.00K-134.00K0-
Gross Margin-55.17%86.06%74.94%25.11%-9.41%-22.83%--
Operating Expense376.00K491.00K750.00K629.14K900.00K2.66M2.08M1.38M-
Operating Income-384.00K-475.00K-466.00K-111.43K-845.00K-2.71M-2.21M-1.38M-3.48M
Operating Margin--1637.93%-141.21%-16.13%-385.84%-499.63%-376.49%--
EBITDA-486.00K-618.00K-352.00K-322.29K-900.00K-2.59M-2.94M-1.38M-5.74M
EBITDA Margin--2131.03%-106.67%-46.65%-410.96%-477.49%-500.51%--
Net Income-494.00K-703.00K-538.00K-274.29K-954.00K-2.71M-3.12M-1.59M-5.74M
Net Income Margin--2424.14%-163.03%-39.70%-435.62%-499.08%-531.52%--
Interest Expense-16.00K72.00K12.00K8.00K4.00K3.00K64.00K0
Interest Expense % of Total Revenue-55.17%21.82%1.74%3.65%0.74%0.51%--

Balance Sheet

Currency: GBP2018-05-312019-05-312020-05-312021-05-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets3.10M2.76M2.59M2.77M3.13M4.94M2.43M3.20M7.58M
Total Liabilities152.00K520.00K890.00K1.22M2.32M385.00K408.00K119.00K1.39M
Total Equity2.94M2.24M1.70M1.54M812.00K4.55M2.03M3.08M6.19M
Cash339.00K90.00K25.00K209.00K598.00K1.64M155.00K757.00K1.72M
Total Debt102.00K405.00K571.00K682.00K950.00K22.00K34.00K-75.00K
Net Debt-237.00K315.00K546.00K473.00K352.00K-1.62M-121.00K-757.00K-1.65M

Cash Flow

Currency: GBP2018-05-312019-05-312020-05-312021-05-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-413.00K-560.00K-192.00K1.00K-254.00K-2.36M-1.24M-1.13M-3.27M
Investing Cash Flow-516.00K-20.00K-8.00K-16.00K-1.00K-718.00K-232.00K-337.00K-
Financing Cash Flow1.33M328.00K128.00K199.00K800.00K4.13M-2.08M4.23M
Capital Expenditure516.00K20.00K8.00K16.00K1.00K718.00K232.00K4.00K0
Free Cash Flow-929.00K-580.00K-200.00K-15.00K-255.00K-3.08M-1.47M-1.13M-3.27M
FCF to OCF224.94%103.57%104.17%-1500.00%100.39%130.42%118.74%100.35%100.00%

Earnings

Report DateSep 30, 2022Apr 27, 2023Sep 30, 2024Dec 31, 2024May 7, 2025Sep 30, 2025
EPS Estimate0.000.00--0.000.00
EPS Actual-0.01-0.02-0.08-0.010.00-0.00
Surprise------
Timing------

Key Statistics & Ratios

Market Cap8.10M
Enterprise Value7.44M
Trailing P/E0.00
Forward P/E0.00
Price / Sales9.59
Price / Book1.47
EPS0.00
Book Value0.001
Revenue (TTM)0
Gross Profit (TTM)0
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-94.61%
Return on Assets-26.57%
Shares Outstanding7.90B
Shares Float5.11B
Beta1.19
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%